You are here

Article info

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer

Authors

  • Fan Sun UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Zong Sheng Guo UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Alyssa D Gregory Department of Medicine, University of Pittsburgh Medical Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Steven D Shapiro Department of Medicine, University of Pittsburgh Medical Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Gutian Xiao UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Zhaoxia Qu UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA PubMed articlesGoogle scholar articles

Citation

Sun F, Guo ZS, Gregory AD, et al
Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer
Journal for ImmunoTherapy of Cancer 2020;8:e000294. doi: 10.1136/jitc-2019-000294
Online issue publication 
January 11, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.